Evidence map›Paper›PMID 40447588›Full record

Articlenpj aging2025

Senolytic effects of a modified Gingerenone A.

Ruin Moaddel, Chad Sanehira, Gregory Keyes, Chang-Yi Cui, Reza Ahmadkhaniha, Julián Candia, Nathan L Price, Sarah Eckroth, Bryce Middleton, Mohammed Khadeer and 7 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in npj aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Ruin MoaddelLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA. moaddelru@mail.nih.gov.
Chad SanehiraTranslational Gerontology Branch, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Gregory KeyesLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Chang-Yi CuiLaboratory of Genetics and Genomics, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Reza AhmadkhanihaLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Julián CandiaTranslational Gerontology Branch, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Nathan L PriceTranslational Gerontology Branch, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Sarah EckrothTranslational Gerontology Branch, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Bryce MiddletonLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Mohammed KhadeerLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Caio H MazucantiLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Ross A McDevittComparative Medicine Section, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Myriam GorospeLaboratory of Genetics and Genomics, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Rafael de CaboTranslational Gerontology Branch, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Josephine M EganLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Christopher E RamsdenLaboratory of Clinical Investigation, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.
Luigi FerrucciTranslational Gerontology Branch, National Institute on Aging, Intramural Research Program, NIH, Baltimore, MD, USA.

Funding

Disease Status Drug MetabolismZ01AG000297 · NIA · NATIONAL INSTITUTE ON AGING · PI WAINER, IRVING WILLIAM · 2002 to 2008
$1.1M
Intramural NIH HHS Z01 AG000297NIH HHS Z01-AG-000297
6 · The paper itself

Abstract

Senescent cells accumulate with aging and are associated with several age-associated diseases and functional declines. Eliminating senescent cells with senolytics improves aging phenotypes in mouse models and may improve the health of people with chronic diseases. To date, very few senotherapeutic (senolytics and senomorphics) compounds have been identified. In a recent study, we reported that gingerenone A (GinA) has a senolytic effect via mechanisms including the activation of caspase-3 activity and apoptotic cell death. In this study, we investigated whether GinA has senotherapeutic properties in a mouse model of senescence. Moreover, we modified GinA with eicosapentaenoic acid (EPA) esters (GinA-EPA) or docosahexaenoic acid (DHA) esters (GinA-DHA) to generate modified gingerenone A (modGinA) that could enhance GinA effects. We found that both GinA and modGinA induced biochemical and histological changes consistent with anti-inflammatory, senolytic, and senomorphic effects, leading to improved metabolic and mitochondrial functions.

Identifiers

PMID40447588
PMCPMC12125167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.